← All Stocks

Moderna, Inc.

MRNA · NMS
$182.11-24.65%
52W Low: $22.2852W High: $192.31
Current: $182.11  ·  94% of 52-week range
HealthcareBiotechnologyNMS
View live charts, options flow & technicals for Moderna, Inc. → Open Dashboard

Moderna, Inc. (MRNA) is a healthcare company in the biotechnology industry with $2.23B in trailing revenue — analyst consensus: hold.

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Key Statistics

Market Cap$72.70B
Revenue (TTM)$2.23B
EPS (TTM)$-7.96
EPS (Fwd est.)$-4.47
Employees4,700
Forward P/E-40.75
Price / Sales32.63
Price / Book10.75
EV / EBITDA-31.37
Beta (5Y)1.11

Analyst Consensus

Consensus
Hold
Analyst Price Target
-34.3% downside
Target: $119.56

Annual Revenue & Net Income

RevenueNet Income
'22
$18.88B
$8.36B
'23
$6.75B
$-4.71B
'24
$3.20B
$-3.56B
'25
$1.92B
$-2.82B

Earnings History


QuarterActual EPSEstimateResult
Jul 2026
$-1.97
$-2.06Beat (+4.3%)
Apr 2026
$-3.40
$-3.88Beat (+12.4%)
Feb 2026
$-2.11
$-2.64Beat (+20.2%)
Nov 2025
$-0.51
$-2.16Beat (+76.4%)

Next Earnings Report

Moderna, Inc. is next expected to report earnings on 05 Nov 2026.

Profitability

-66.0%
-557.9%
-141.4%
Gross
Margin
Operating
Margin
Net
Margin
Revenue Growth (YoY)2.1%
Return on Equity-39.0%
Return on Assets-13.3%

Balance Sheet

Cash & Equivalents$5.14B
Total Debt$1.29B
Net Position$3.85B (net cash)
Free Cash Flow (TTM)$300.00M
Debt / Equity19.04

Share Ownership

Institutions 80.5%
Insiders 7.3%
Public 12.2%

Related Stocks

LLYUNHJNJMRKABBVTMOPFEISRG

Frequently Asked Questions

What does Moderna, Inc. (MRNA) do?
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses inclu…
What is MRNA's market cap?
Moderna, Inc. has a market capitalization of approximately $72.70B.
How much revenue does MRNA generate?
Moderna, Inc. generated $2.23B in trailing 12-month revenue.
What do analysts say about MRNA?
The analyst consensus rating for Moderna, Inc. is hold, with a mean price target of $119.56. That implies -34.3% upside from the current price.
When does MRNA report earnings?
Moderna, Inc. is next scheduled to report earnings on 05 Nov 2026.
Does MRNA pay a dividend?
Moderna, Inc. does not currently pay a regular dividend.

View live charts, options flow, gamma exposure, earnings history, and technical analysis for Moderna, Inc. on Apsis Markets.

Open Live Dashboard →